Drug
Combigan
Combigan is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Completed1
Withdrawn1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (33.3%)
N/A2 (66.7%)
Trials by Status
completed133%
withdrawn133%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
NCT03235232
withdrawnnot_applicable
Prophylaxis for Anti-VEGF-induced IOP Elevation
NCT02623023
unknownnot_applicable
The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema
NCT02718547
Clinical Trials (3)
Showing 3 of 3 trials
NCT03235232Phase 3
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
NCT02623023Not Applicable
Prophylaxis for Anti-VEGF-induced IOP Elevation
NCT02718547Not Applicable
The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3